MHRA seizes over 8 million fake pregabalin doses in five years
More than 8 million doses of counterfeit pregabalin have been seized over a five-year period, according to figures obtained through a Freedom of Information request. The MHRA, which oversees medicines regulation in the UK, confirmed it takes reports of fatal outcomes linked to fake medicines "very seriously."
What happened
A FOI request has brought to light the scale of counterfeit pregabalin circulating in the UK supply chain. Over a five-year window, the MHRA seized more than 8 million doses of the fake medicine — figures that point to a sustained and significant problem with this particular drug.
Pregabalin is a medicine used to treat neuropathic pain, epilepsy, and generalised anxiety disorder. It has a well-documented history of misuse and diversion, which makes it an attractive target for counterfeiters. The MHRA's seizure data suggests counterfeit versions have been entering the UK at considerable volume over an extended period.
The FOI data came to light via Chemist+Druggist, which reported the MHRA's acknowledgement that fatal outcome reports connected to counterfeit medicines are treated as a serious concern.
Why it matters
Counterfeit pregabalin is not simply a regulatory inconvenience. These are doses of unknown provenance, unknown strength, and unknown composition reaching people who may believe they are taking a legitimate medicine. The risks are real — a patient managing neuropathic pain or a seizure disorder who unknowingly takes counterfeit medicine could receive too little active ingredient, too much, or something else entirely.
For people who use pregabalin for anxiety or chronic pain, the consequences of an underdosed or adulterated counterfeit could range from poor symptom control to acute harm. The MHRA's reference to fatal outcome reports gives a sense of how seriously the regulator regards this.
The scale here is striking. Eight million doses over five years is not small-batch seizure activity — it reflects a supply chain problem that the MHRA has had to pursue consistently over years. That level of counterfeit activity around a single medicine raises questions about how and where these doses were entering the market, and how many got through before being intercepted.
For pharmacists, this kind of data reinforces the point that medicines safety goes well beyond what happens at the dispensing counter. The supply chain itself carries risk, and the regulatory apparatus exists precisely to catch problems before they reach patients. When it works — as it did here, repeatedly, over five years — that matters.
Pregabalin is also a medicine with specific legal controls in the UK, which adds another layer of complexity to its misuse and counterfeiting. Pharmacists working in dispensary settings are already required to handle it carefully. The existence of a large counterfeit market around it is a reminder that the risks associated with this medicine do not disappear at the point of dispensing — they start much earlier in the supply chain.
There's also a public-facing dimension here. Patients who obtain pregabalin outside regulated channels — whether online, through informal networks, or from unlicensed sources — are the ones most exposed to counterfeit product. Pharmacists are often the last point of contact before a patient takes a medicine. That puts them in a position where recognising the signs of possible counterfeit product, knowing how to report concerns, and being able to advise patients on the risks of unregulated supply are all practical skills, not just theoretical knowledge.
GPhC exam relevance
The GPhC Common Registration Assessment tests candidates on medicines regulation, supply chain safety, and the pharmacist's role in identifying and reporting concerns about product quality. This story connects to several of those areas.
Medicines counterfeiting sits within the broader topic of supply chain integrity. The MHRA's role as the UK medicines regulator — responsible for licensing, pharmacovigilance, and enforcement — is a testable area. Understanding what the MHRA does, when to report a suspected counterfeit medicine, and how the Yellow Card scheme fits into pharmacovigilance are all areas worth knowing clearly.
Pregabalin itself is a medicine that appears across multiple exam topic areas. Its therapeutic uses — neuropathic pain, epilepsy, generalised anxiety disorder — are covered in clinical sections. Its legal classification and the requirements that come with that status are covered in law and ethics sections. Its misuse potential is relevant to consultations and patient safety discussions.
When a news story touches a medicine that appears across multiple parts of the curriculum, it's worth using it as a prompt to check your knowledge across all of them. What does pregabalin treat? What are its adverse effects? What are the legal requirements around supplying it? What would you do if a patient told you they had obtained pregabalin from an online source you didn't recognise?
On the regulatory side, the exam may test your understanding of what pharmacists are expected to do when they suspect a medicine may be counterfeit or substandard. The MHRA operates a reporting route for this — knowing it exists and when to use it is a practical piece of knowledge.
The MHRA's statement that it takes fatal outcome reports "very seriously" is also worth registering from an exam perspective. Pharmacovigilance — the monitoring of medicines once they are in use, including adverse events and safety signals — is a GPhC exam topic. Counterfeit medicines that cause harm feed into that system, and pharmacists are part of the reporting infrastructure.
What's next
Watch for any further detail from the MHRA on how these seizures were made — whether through border controls, online marketplace monitoring, or intelligence-led activity. That context would help clarify where the counterfeit supply chain is weakest and where the regulator is focusing its enforcement effort.
If you're preparing for the assessment, use this story to revisit the MHRA's remit and the reporting mechanisms available to pharmacists when product quality is in doubt. The Yellow Card scheme covers suspected adverse reactions, but there is a separate route for reporting concerns about counterfeit or substandard medicines — make sure you know the difference.
Also worth reviewing: pregabalin's therapeutic profile, its legal status, and the specific requirements that apply to medicines in its category. Not because this story tells you to, but because it's a medicine that turns up repeatedly in real pharmacy practice and in assessment questions.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/regulation/over-8m-doses-of-fake-pregabalin-seized-in-last-five-years-NQEQ2ARTMNHCRCVANZZLM5FDWY/